Switch theme
Sign up to access all valuation multiples
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. It has two geographic segments Europe/Asia and USA. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities.
1971
2.2K+
LTM Revenue $767M
LTM EBITDA $221M
$4.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bachem has a last 12-month revenue (LTM) of $767M and a last 12-month EBITDA of $221M.
In the most recent fiscal year, Bachem achieved revenue of $727M and an EBITDA of $214M.
Bachem expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bachem valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $767M | XXX | $727M | XXX | XXX | XXX |
| Gross Profit | $231M | XXX | $219M | XXX | XXX | XXX |
| Gross Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $221M | XXX | $214M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $165M | XXX | $160M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $146M | XXX | $144M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bachem's stock price is CHF 52 (or $62).
Bachem has current market cap of CHF 3.9B (or $4.7B), and EV of CHF 3.8B (or $4.5B).
See Bachem trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.5B | $4.7B | XXX | XXX | XXX | XXX | $1.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bachem has market cap of $4.7B and EV of $4.5B.
Bachem's trades at 6.2x EV/Revenue multiple, and 21.2x EV/EBITDA.
Equity research analysts estimate Bachem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bachem has a P/E ratio of 31.9x.
See valuation multiples for Bachem and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV (current) | $4.5B | XXX | $4.5B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | 20.5x | XXX | 21.2x | XXX | XXX | XXX |
| EV/EBIT | 27.5x | XXX | 28.4x | XXX | XXX | XXX |
| EV/Gross Profit | 19.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 31.9x | XXX | 32.2x | XXX | XXX | XXX |
| EV/FCF | -30.1x | XXX | -27.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBachem's last 12 month revenue growth is 24%
Bachem's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $27K for the same period.
Bachem's rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bachem's rule of X is 89% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bachem and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 54% | XXX | 54% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 89% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bachem acquired XXX companies to date.
Last acquisition by Bachem was XXXXXXXX, XXXXX XXXXX XXXXXX . Bachem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bachem founded? | Bachem was founded in 1971. |
| Where is Bachem headquartered? | Bachem is headquartered in Switzerland. |
| How many employees does Bachem have? | As of today, Bachem has 2.2K+ employees. |
| Is Bachem publicy listed? | Yes, Bachem is a public company listed on SWX. |
| What is the stock symbol of Bachem? | Bachem trades under BANB ticker. |
| When did Bachem go public? | Bachem went public in 2001. |
| Who are competitors of Bachem? | Similar companies to Bachem include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of Bachem? | Bachem's current market cap is $4.7B |
| What is the current revenue of Bachem? | Bachem's last 12 months revenue is $767M. |
| What is the current revenue growth of Bachem? | Bachem revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Bachem? | Current revenue multiple of Bachem is 5.9x. |
| Is Bachem profitable? | Yes, Bachem is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bachem? | Bachem's last 12 months EBITDA is $221M. |
| What is Bachem's EBITDA margin? | Bachem's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Bachem? | Current EBITDA multiple of Bachem is 20.5x. |
| What is the current FCF of Bachem? | Bachem's last 12 months FCF is -$150M. |
| What is Bachem's FCF margin? | Bachem's last 12 months FCF margin is -20%. |
| What is the current EV/FCF multiple of Bachem? | Current FCF multiple of Bachem is -30.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
